Literature DB >> 9266855

Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits.

Y M Kuo1, M R Emmerling, A S Woods, R J Cotter, A E Roher.   

Abstract

From the neuritic plaques and vascular walls of the brains of patients with Alzheimer disease, we have purified and quantified an A beta peptide which starts at residue 3Glu in the form of pyroglutamyl (A beta3pE). The N-terminally truncated A beta3pE comprised 51% of the A beta in the neuritic plaques. This was followed by 30% starting at position 1Asp which included 20% in the isomerized form (IsoAsp). In contrast, the vascular amyloid only contained an average of 11% in the form of A beta3pE with the major component starting at residue 1Asp (69%), which included only 6% in the form of IsoAsp. The presence of A beta3pE has important structural consequences since it is more hydrophobic than other forms of A beta, thus increasing the insolubility of A beta. In addition, A beta3pE, with its blocked N-terminus to the action of common aminopeptidases, may result in the profuse accumulation of A beta in the neuritic plaques of Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266855     DOI: 10.1006/bbrc.1997.7083

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  50 in total

1.  Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation.

Authors:  Melanie R Nilsson; Miles Driscoll; Daniel P Raleigh
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

2.  Amyloid-beta peptide Abetap3-42 affects early aggregation of full-length Abeta1-42.

Authors:  Hiromi M Sanders; Robert Lust; Jan K Teller
Journal:  Peptides       Date:  2009-02-11       Impact factor: 3.750

Review 3.  Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions.

Authors:  Tyler A Kokjohn; Alex E Roher
Journal:  Alzheimers Dement       Date:  2009-07       Impact factor: 21.566

4.  Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Authors:  Alex E Roher; Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Jesse M Hunter; Marwan N Sabbagh; Thomas G Beach
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 6.  Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Authors:  Julie Dunys; Audrey Valverde; Frédéric Checler
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

7.  Phagocytosis and LPS alter the maturation state of β-amyloid precursor protein and induce different Aβ peptide release signatures in human mononuclear phagocytes.

Authors:  Philipp Spitzer; Martin Herrmann; Hans-Wolfgang Klafki; Alexander Smirnov; Piotr Lewczuk; Johannes Kornhuber; Jens Wiltfang; Juan Manuel Maler
Journal:  J Neuroinflammation       Date:  2010-10-07       Impact factor: 8.322

8.  The biochemical aftermath of anti-amyloid immunotherapy.

Authors:  Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Eliezer Masliah; James Ar Nicoll; Marwan N Sabbagh; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Mol Neurodegener       Date:  2010-10-07       Impact factor: 14.195

9.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.